Skip to main content
OpenTrials
Completed

NCT Number: NCT07655466

Effects of Seed Cycling Capsules on Premenstrual Syndrome Symptoms and Menstrual Cycle Length

This virtual, single-arm clinical trial will evaluate the effects of Seed Cycling Capsules on symptoms associated with premenstrual syndrome (PMS) and menstrual cycle characteristics. Forty female participants aged 18 to 45 years will use the study products daily for two menstrual cycles. Participants will complete questionnaires at baseline, at the end of their period during Cycle 1, and at the end of their period during Cycle 2.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Premenstrual Syndrome Menstrual Symptoms Menstruation Disturbances Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year–45 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Las Vegas, Nevada, 89118, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be female.
  • Be 18-45 years of age.
  • Have experienced at least five of the following symptoms during the last three menstrual cycles:

Heavy flow Prolonged, shortened, or irregular periods Headaches or migraines Low mood Fatigue Bloating Premenstrual or menstrual cramps Breast tenderness Poor sleep Constipation or diarrhea Weight gain or fluctuations Irritability or anger Sick days or reduced social activity due to menstrual symptoms Hormonal acne

  • Be generally healthy.
  • Have a menstrual cycle length between 23 and 35 days.
  • Track menstrual cycles and be able to predict period dates.
  • Be willing to refrain from taking products, medications, or supplements targeting menstrual health during the study.

Exclusion criteria

  • Use of hormonal contraception.
  • Allergy to sesame.
  • Chronic conditions that would interfere with study participation, including oncological and psychiatric disorders.
  • Pregnant, breastfeeding, or trying to conceive.
  • Unwillingness to follow the protocol.
  • Menopause or menopausal symptoms.
  • Recent or planned invasive medical procedures.
  • History of substance abuse.
  • Diabetes or other endocrine-related conditions.
  • Current or planned participation in another research study.
  • Use of hormone-modulating medications or therapies.
  • Planned insertion or replacement of an IUD within 12 weeks.
  • Diagnosis of endometriosis, polycystic ovary syndrome (PCOS), or adenomyosis.

Treatment and study plan

Two Moons Seed Cycling Capsules

Dietary Supplement

Participants will take Two Moons Seed Cycling Capsules daily for two menstrual cycles. Participants will take two capsules with the first meal of the day according to the following schedule: Zest Capsules from Days 1-14 of the cycle, and Zen Capsules from Days 15-28 of the cycle. Participants will continue this schedule for two menstrual cycles regardless of when subsequent menstrual periods occur.

Primary outcomes

  1. Change in Menstrual Cramp Severity

    Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

    Self-reported severity of premenstrual and menstrual cramps assessed using study questionnaires and compared between Baseline, Cycle 1, and Cycle 2.

  2. Change in Bloating Severity

    Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

    Self-reported severity of abdominal bloating associated with the menstrual cycle assessed using study questionnaires.

  3. Change in Fatigue Severity

    Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

    Self-reported fatigue associated with the menstrual cycle assessed using study questionnaires.

  4. Change in Hormonal Acne Severity

    Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

    Self-reported severity and frequency of hormonal acne symptoms assessed using study questionnaires.

  5. Change in Mood Symptoms

    Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

    Self-reported mood-related symptoms including low mood, irritability, and anger associated with the menstrual cycle.

  6. Change in Sleep Quality

    Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

    Self-reported sleep quality and insomnia symptoms associated with the menstrual cycle.

  7. Change in Breast Tenderness Severity

    Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

    Self-reported breast tenderness associated with the menstrual cycle.

  8. Change in Libido

    Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

    Self-reported sex drive and libido associated with the menstrual cycle.

Secondary outcomes

  1. Participant Assessment of Overall Menstrual Experience

    Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

    Participant-reported assessment of the overall effect of the study product on menstrual health and menstrual cycle experience.

  2. Participant Satisfaction With Seed Cycling Capsules

    Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

    Participant-reported satisfaction with the study product following use during the study period.

  3. Participant Perception of Product Effectiveness

    Time frame: Day 28 (end of first 28-day intervention cycle), and Day 56 (end of second 28-day intervention cycle)

    Participant-reported perception of the effectiveness of the study product in improving menstrual symptoms.

Sponsors and collaborators

Lead sponsor

Superlune Inc. d/b/a Two Moons Health

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jun 17, 2026
Registry last updated
Jun 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.